https://doi.org/10.1158/1078-0432.ccr-11-2121
J
John Nemunaitis
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
807
Papers
35.7K
Citations
92
h-index
349
i10-index
John Nemunaitis is an academic researcher from Gradalis (United States). The author has contributed to research in topics: Virus-based gene therapy research & Cancer Research and Treatments & CAR-T cell therapy research. The author has an h-index of 92, co-authored 686 publications.
ORCID: 0000-0002-2234-2381Papers by this author
worksA Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
2011 · Clinical Cancer Research · 361 citations
A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
2009 · Molecular Therapy · 265 citations
https://doi.org/10.1038/mt.2009.262
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
2020 · Journal of Clinical Oncology · 164 citations
https://doi.org/10.1200/jco.19.02085
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
2013 · Journal of Translational Medicine · 127 citations
https://doi.org/10.1186/1479-5876-11-259
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
2016 · Molecular Therapy · 94 citations
https://doi.org/10.1038/mt.2016.86
Homologous recombination proficiency in ovarian and breast cancer patients
2021 · BMC Cancer · 83 citations
https://doi.org/10.1186/s12885-021-08863-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat